ω-3 Fatty Acids in Pediatric Major Depressive Disorder
JAMA Network Open · 02.01.2026 · 9 (1) · e2548703
DOI: 10.1001/jamanetworkopen.2025.48703 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 02.01.2026. Verfasst von Gregor Berger und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, University of Zürich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Major Depressive Disorder, Fatty Acids, Omega-3, Dietary Supplements. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Meta-analyses of ω-3 fatty acids for depression have reported inconsistent results, and pediatric evidence is sparse. Promotion of unproven supplements may delay evidence-based care.
Objective
To evaluate whether adjunctive ω-3 fatty acid supplementation improves outcomes in moderate-to-severe pediatric major depressive disorder (MDD). Design, Setting, and Participants In a multicenter, double-blind, placebo-controlled randomized clinical trial at 5 Swiss child and adolescent psychiatry centers, 257 youths with MDD were enrolled and randomized between April 28, 2017, and March 24, 2022, and followed up for 36 weeks, with final analysis from July 1, 2022, to January 26, 2023. Analysis was based on intention to treat.
Interventions
Participants received ω-3 fatty acids, 1.5 g/d (1 g of eicosapentaenoic acid [EPA] and 0.5 g of docosahexaenoic acid [DHA], 2:1 ratio), or medium-chain triglyceride placebo in combination with standardized psychotherapy. Antidepressant use was permitted per national guidelines. Main Outcomes and Measures The primary outcome was the trajectory of Children’s Depression Rating Scale–Revised (CDRS-R) scores analyzed with a joint mixed-effects and time-to-event model accounting for dropout or initiation of off-trial antidepressant therapy. Secondary outcomes included response (≥30% reduction in CDRS-R scores), remission (CDRS-R score ≤28), self-rated depression, quality of life, suicidality, and safety.
Results
Of 257 randomized participants (mean [SD] age, 15.7 [1.7] years; 188 [73.2%] female; mean [SD] CDRS-R score, 58.5 [8.8]), 129 received ω-3 supplements and 128 received placebo. The mean (SD) CDRS-R scores decreased similarly in both groups: at 12 weeks, 45.93 (11.98) vs 46.08 (12.99); at 36 weeks, 36.50 (13.12) vs 36.83 (15.46). The adjusted mean difference in CDRS-R scores was 0.77 (95% CI, −1.39 to 2.93; P = .49) points. The hazard ratio for time to dropout was 1.22 (95% CI, 0.83-1.79; P = .32). Response occurred in 34 of 109 (31.2%) ω-3 recipients vs 43 of 110 (39.1%) placebo recipients at 12 weeks; remission occurred at 36 weeks in 30 of 94 ω-3 recipients (31.9%) vs 37 of 90 (41.1%) placebo recipients (all differences were nonsignificant). Secondary measures and suicidality improved without between-group differences. EPA plus DHA levels expressed by the ω-3 index rose by a mean (SD) of 4.33% (1.54%) and 4.88% (2.38%) at 12 and 36 weeks, respectively, in the ω-3 arm, confirming adherence. A total of 76 serious adverse events were reported in 97 participants, with 31 occurring in the placebo arm and 45 in the ω-3 arm. These included 28 suicide attempts, but no deaths or permanent disabilities. None of these were judged to be causally related to the study medication. Conclusions and Relevance In this randomized clinical trial, adjunctive ω-3 administration, 1.5 g/d (EPA:DHA, 2:1), did not outperform placebo in youths with MDD. Future work should assess EPA-enriched formulations and biomarker-guided approaches. Trial Registration ClinicalTrials.gov Identifier: NCT03167307
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, University of Zürich, Zürich, Switzerland.
- Psychiatry St Gallen, Wil St Gallen, St Gallen, Switzerland.
- Department of Child and Adolescent Forensic Psychiatry, University Hospital of Psychiatry, Zurich, Switzerland.
- Department of Clinical Research, University of Basel, Basel, Switzerland.
- Clienia Littenheid AG, Winterthur, Switzerland.
- Child and Adolescent Psychiatric Services St Gallen, St Gallen, Switzerland.
Zitieren
APA
Berger, G., Häberling, I., Emery, S., Albermann, M., Baumgartner, N., Nalani, K., Strumberger, M., Wöckel, L., Erb, S., Bachmann, S., Müller-Knapp, U., Contin-Waldvogel, B., Yamini, A., Rhiner, B., Drechsler, R., Held, U., Reeve, K., Heinz, P., Pauli, D., …, & Omega-3 pMDD Study Group (2026). ω-3 Fatty Acids in Pediatric Major Depressive Disorder. JAMA Network Open, 9(1), e2548703. https://doi.org/10.1001/jamanetworkopen.2025.48703
Vancouver
Berger G, Häberling I, Emery S, Albermann M, Baumgartner N, Nalani K, et al. ω-3 Fatty Acids in Pediatric Major Depressive Disorder. JAMA Network Open. 2026;9(1):e2548703. doi:10.1001/jamanetworkopen.2025.48703
BibTeX
@article{Berger2026,
author = {Berger, Gregor and Häberling, Isabelle and Emery, Sophie and Albermann, Mona and Baumgartner, Noemi and Nalani, Kristin and Strumberger, Michael and Wöckel, Lars and Erb, Suzanne and Bachmann, Silke and Müller-Knapp, Ulrich and Contin-Waldvogel, Brigitte and Yamini, Amir and Rhiner, Bruno and Drechsler, Renate and Held, Ulrike and Reeve, Kelly and Heinz, Priska and Pauli, Dagmar and Schmeck, Klaus and Hersberger, Martin and Walitza, Susanne and Omega-3 pMDD Study Group, Omega-3 pMDD Study Group},
title = {ω-3 Fatty Acids in Pediatric Major Depressive Disorder},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {1},
pages = {e2548703},
doi = {10.1001/jamanetworkopen.2025.48703}
}
EUVIMED